A- A A+

Treating anxious syndromes with pregabalin in patients with psychosis. 

Garel N, Bloom D, Joober R. 

J Psychiatry Neurosci. 2020;45(5):370. doi:10.1503/jpn.200033


Gabapentin for Post-Hospitalization Alcohol Relapse Prevention; Should Gabapentin Be Considered for FDA Approval in the Treatment of Alcohol Use Disorder?: A Case Presentation and Literature Review. 

Neuhut S. 

Cureus. 2020;12(6):e8931. Published 2020 Jun 30. doi:10.7759/cureus.8931


Is the non-medical use of pregabalin related to reward/relief craving coupled to an unbalanced opioid system?

Della Rocca F., Cosentino V., Carbone M.G., Maremmani A.G.I., and Maremmani I.

Conclusions: This paper adds to the growing body of literature suggesting that pregabalin has a non-medical use potential. When prescribing pregabalin, clinicians should consider completing a risk assessment for non-medical use, especially in patients with a Substance Use Disorder history. Therefore, pregabalin off-label prescriptions should be carefully considered.

Heroin Addiction and Related Clinical Problems, Published Ahead of Print, July 14, 2020

Is the non-medical use of pregabalin related to reward/relief craving coupled to an unbalanced opioid system?

Gabapentin-induced drug-seeking-like behavior: a potential role for the dopaminergic system.

Althobaiti YS, Alghorabi A, Alshehri FS, et al. 

Sci Rep. 2020;10(1):10445. Published 2020 Jun 26. doi:10.1038/s41598-020-67318-6


Australien. Pregabalin use found to be relatively common among people who regularly inject drugs

The use of pregabalin, a medicine for neuropathic pain, is relatively common among a sample of people who regularly inject drugs (PWID) in Australia, a new study by researchers at the National Drug and Alcohol Research Centre (NDARC), UNSW Sydney has found. 

In a sample of 905 participants from the 2018 Illicit Drug Reporting System, it was identified that 25 per cent of PWID reported using pregabalin in the previous six months.

Lead author, Dr Rachel Sutherland said; “10 per cent of the sample reported using pregabalin that was prescribed to them, while 15 per cent reported using pregabalin that was not prescribed to them.” (ndarc - National Drug and Alcohol Research Centre, Australien, 17.06.2020)


Problematic Medication With Benzodiazepines, "Z-drugs", and Opioid Analgesics.

Buth S, Holzbach R, Martens MS, Neumann-Runde E, Meiners O, Verthein U.

Dtsch Arztebl Int. 2019 Sep 13;116(37):607-614. doi: 10.3238/arztebl.2019.0607.


A study of the reasons for prescribing and misuse of gabapentinoids in prison including their co-prescription with opioids and antidepressants.

Soni A, Walters P.

Int J Prison Health. 2019 Aug 27;16(1):67-77. doi: 10.1108/IJPH-01-2019-0004.



Pregabalin induced visual hallucinations - a rare adverse reaction.

Mousailidis G, Papanna B, Salmon A, Sein A, Al-Hillawi Q.

BMC Pharmacol Toxicol. 2020 Feb 28;21(1):16. doi: 10.1186/s40360-020-0395-6.


Pregabalin Abuse in Combination With Other Drugs: Monitoring Among Methadone Patients.

Lancia M, Gambelunghe A, Gili A, Bacci M, Aroni K, Gambelunghe C.

Front Psychiatry. 2020 Feb 11;10:1022. doi: 10.3389/fpsyt.2019.01022. 


Alkoholkrankheit: Gabapentin erleichtert in Studie Abstinenz

Charleston/South Carolina –Das Antiepileptikum Gabapentin, das bei der Alkoholkrank­heit die Entzugssymptome lindert, hat in einer randomisierten kontrollierten Studie bei ausgesuchten Patienten den Alkoholkonsum gesenkt und eine Abstinenz erleichtert. Dies zeigen die jetzt in JAMA Internal Medicine (2020; doi: 10.1001/jamainternmed.2020.0249) veröffentlichten Ergebnisse. (aerzteblatt.de, 10.03.2020)


Efficacy of Gabapentin for the Treatment of Alcohol Use Disorder in Patients With Alcohol Withdrawal Symptoms: A Randomized Clinical Trial.

Anton RF, Latham P, Voronin K, et al. 

JAMA Intern Med. Published online March 09, 2020. doi:10.1001/jamainternmed.2020.0249



Trends, Patient and Prescriber Characteristics in Gabapentinoid Use in a Sample of United States Ambulatory Care Visits from 2003 to 2016.

Zhou L, Bhattacharjee S, Kwoh CK, Tighe PJ, Malone DC, Slack M, Wilson DL, Brown JD, Lo-Ciganic WH.

J Clin Med. 2019 Dec 29;9(1). pii: E83. doi: 10.3390/jcm9010083.


Electroretinographic abnormalities associated with pregabalin: a case report.

Ninomiya W, Mizobuchi K, Hayashi T, Okude S, Katagiri S, Kubo A, Masuhara N, Nakano T.

Doc Ophthalmol. 2020 Jan 3. doi: 10.1007/s10633-019-09743-1. 



Prescribed and non-prescribed gabapentin use among persons seeking inpatient opioid detoxification.

Stein MD, Kenney SR, Anderson BJ, Conti MT, Bailey GL.

J Subst Abuse Treat. 2020 Mar;110:37-41. doi: 10.1016/j.jsat.2019.12.007. 



Pain And The Use Of Gabapentinoids In German Nursing Home Residents - Results From An Analysis Based On Statutory Health Insurance Data.

Bantel C, Hoffmann F, Jobski K.

J Pain Res. 2019 Nov 22;12:3175-3184. doi: 10.2147/JPR.S221579.


Warnung der FDA zu Gabapentin und Pregabalin: Bei Risikopersonen und in der Kombi mit Opioiden droht Atemdepression

Gabapentin und Pregabalin in Kombination mit Opioiden oder mit anderen Arzneimitteln, welche das zentrale Nervensystem (ZNS) dämpfen, können lebensgefährliche Atemprobleme verursachen. Davor hat jetzt die amerikanische Arzneimittelbehörde FDA gewarnt [1]. (Medscape, 02.01.2020)


USA. FDA In Brief: FDA requires new warnings for gabapentinoids about risk of respiratory depression

“With the evolution of the opioid crisis, getting ahead of new concerns or addressing those that are already evident requires examining signs of misuse and abuse as soon as any signal emerges.
Reports of gabapentinoid abuse alone, and with opioids, have emerged and there are serious consequences of this co-use, including respiratory depression and increased risk of opioid overdose death.“ (FDA - U. S. Food and Drug Administration, USA, 19.12.2019)


The relationship between the reporting of euphoria events and early treatment responses to pregabalin: an exploratory post-hoc analysis.

Parsons B, Freynhagen R, Schug S, Whalen E, Ortiz M, Bhadra Brown P, Knapp L.

J Pain Res. 2019 Aug 22;12:2577-2587. doi: 10.2147/JPR.S199203. 


Intranasal Pregabalin Administration: A Review of the Literature and the Worldwide Spontaneous Reporting System of Adverse Drug Reactions.

Elsayed M, Zeiss R, Gahr M, Connemann BJ, Schönfeldt-Lecuona C.

Brain Sci. 2019 Nov 13;9(11). pii: E322. doi: 10.3390/brainsci9110322.


Prescription of benzodiazepines, z-drugs, and gabapentinoids and mortality risk in people receiving opioid agonist treatment: Observational study based on the UK Clinical Practice Research Datalink and Office for National Statistics death records.

Macleod J, Steer C, Tilling K, Cornish R, Marsden J, Millar T, Strang J, Hickman M.

PLoS Med. 2019 Nov 26;16(11):e1002965. doi: 10.1371/journal.pmed.1002965. 


Trends in gabapentin and baclofen exposures reported to U.S. poison centers,

Kimberly Reynolds, Robert Kaufman, Amanda Korenoski, Laura Fennimore, Joshua Shulman & Michael Lynch (2019) 

Clinical Toxicology, DOI: 10.1080/15563650.2019.1687902 


Pregabalin: Potential for Addiction and a Possible Glutamatergic Mechanism.

Althobaiti YS, Almalki A, Alsaab H, Alsanie W, Gaber A, Alhadidi Q, Hardy AMG, Nasr A, Alzahrani O, Stary CM, Shah ZA.

Sci Rep. 2019 Oct 22;9(1):15136. doi: 10.1038/s41598-019-51556-4.


Negative myoclonus associated with pregabalin.

Park KD, Kim MK, Lee SJ.

Yeungnam Univ J Med. 2018 Dec;35(2):240-243. doi: 10.12701/yujm.2018.35.2.240. 


Medicines associated with dependence or withdrawal: a mixed-methods public health review and national database study in England.

Marsden J, White M, Annand F, Burkinshaw P, Carville S, Eastwood B, Kelleher M, Knight J, O'Connor R, Tran A, Willey P, Greaves F, Taylor S.

Lancet Psychiatry. 2019 Nov;6(11):935-950. doi: 10.1016/S2215-0366(19)30331-1.


Increasing Worldwide Evidence of Harms Associated With Gabapentinoids, Particularly Pregabalin

With increased use of gabapentinoids (gabapentin and pregabalin) for a wide a variety of indications, there has been growing evidence of harms. Two recent studies—one in Sweden and the other in Australia—looked at national data to investigate harms associated with gabapentinoid use. (Alcohol, Other Drugs, and Health: Current Evidence, Boston University, USA, 29.10.2019) 


Rising pregabalin use and misuse in Australia: trends in utilization and intentional poisonings.

Cairns R, Schaffer AL, Ryan N, Pearson SA, Buckley NA.

Addiction. 2019 Jun;114(6):1026-1034. doi: 10.1111/add.14412. Epub 2018 Sep 5.



Baden-Württemberg. Suchtforum der Landesstelle: „Drogenabhängigkeit und Medikamentenmissbrauch“ - 26.09.2019

(…) In den letzten Jahren spielt der Medikamentenmissbrauch bei Drogenabhängigen eine immer größere Rolle. Neben der Tatsache, dass in der Drogenszene alle dem BtMG unterliegenden Medikamente, wie Subutex, Polamidon und andere Opioide, aber auch Methylphenidat zu sehr günstigen Preisen gehandelt werden, haben wir in den letzten Jahren den zunehmenden Trend, dass sich Dro-genabhängige von Fach-und Hausärzten unterschiedliche psychotrop wirksame Medikamente verschreiben lassen. Hier sind insbesondere die Benzodiazepine zu nennen und - in immer stärkerem Maße - der Missbrauch von Pregabalin (Lyrica). Andere Psychopharmaka bis hin zu Antidepressiva werden ebenfalls als Beikonsum zu den klassischen illegalen Drogen missbraucht. (Landesstelle für SuchtfragenderLiga der freien Wohlfahrtspflegein Baden-Württemberg e.V., Landesstellenbrief, 08/2019, 24.10.2019)


Prescribing trends of gabapentin, pregabalin, and oxycodone: a secondary analysis of primary care prescribing patterns in England

Katlyn Green, Nora Cooke O'Dowd, Hilary Watt, Azeem Majeed, Richard J Pinder

BJGP bjgpopen.org/content/early/2019/09/16/bjgpopen19X101662 Open 17 September 2019; bjgpopen19X101662. DOI: 10.3399/bjgpopen19X101662


A case of gabapentin overdose induced rhabdomyolysis requiring renal replacement therapy.

Qiu X, Tackett E, Khitan Z.

Clin Case Rep. 2019 Jul 11;7(8):1596-1599. doi: 10.1002/ccr3.2302. 


Effectiveness of Gabapentin in Reducing Cravings and Withdrawal in Alcohol Use Disorder: A Meta-Analytic Review.

Ahmed S, Stanciu CN, Kotapati PV, Ahmed R, Bhivandkar S, Khan AM, Afridi A, Qureshi M, Esang M.

Prim Care Companion CNS Disord. 2019 Aug 22;21(4). pii: 19r02465. doi: 10.4088/PCC.19r02465.